ClinicalTrials.gg
Not yet recruitingNCT07529925Updated Apr 14, 2026

A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque Psoriasis

A Phase 4 interventional study of Adalimumab Solution for Injection in Severe Plaque Psoriasis in Chinese Children, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Not yet recruiting. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
4 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.

Planned enrollment
41st of 48
30 · median 148
Started
2026
with 1 other
Phase 4
11 of 48
2 open now
Registered
48th of 48
by date

Among the 48 studies testing adalimumab in Psoriasis, this one is the 41st largest by planned enrollment, is one of 2 that started in 2026, is one of 11 in phase 4, and was the 48th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 4 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing adalimumab in Psoriasis, or all of them as a file.
02

Study summary

This study is a real-world clinical study of adalimumab. The project plans to enrol 30 participants and aims to evaluate the efficacy and safety of adalimumab in Chinese children with plaque psoriasis, with the primary endpoint being the proportion of participants achieving PASI 75 (PASI score reduction ≥75% from baseline) at week 16.

03

Conditions studied

  • Severe Plaque Psoriasis in Chinese Children

Browse trials for

04

Who can participate

Ages eligible
4 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects and their guardians must sign an form. The research protocol/informed consent form for data collection and data verification should comply with local laws and regulations.
  • Age 4 years ≤ age ≤ 17 years, regardless of gender;
  • Subjects weigh ≥ 15kg;
  • Subjects who respond poorly to local treatment and/or phototherapy or are unsuitable for such treatments;
  • Diagnosed with severe plaque psoriasis in children according to the "Chinese Expert Consensus on the Diagnosis and Treatment of Pediatric Psoriasis (2021)"

Exclusion criteria

Exclusion Criteria:

  • Based on the prescribing information of Adalimumab Solution for Injection and the judgment of the treating physician, the subject is not eligible for treatment with Adalimumab Solution for Injection;
  • Subjects who received psoralen combined with long-wave ultraviolet (UVA) therapy within 14 days prior to the screening period, or topical medium-wave ultraviolet (UVB) therapy within 7 days prior to the screening period;
  • Subjects who received non-biological systemic treatments for paediatric psoriasis within 14 days prior to the screening period;
  • Subjects who are currently using or have used other biological Disease-Modifying Antirheumatic Drug treatments within 12 weeks prior to the screening period;
  • Subjects with significantly active psoriasis within 12 weeks prior to enrolment;
  • Subjects who have received any within 3 months prior to the first dose of Adalimumab Solution for Injection, or who plan to receive live vaccines during the study;
  • Subjects currently participating in other clinical studies;
  • Subjects deemed unsuitable for participation in this trial by the investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Adalimumab Solution for Injection 20mg/40mg

    For a body weight of 15 kg\~30 kg, the initial dose is 20 mg, with 20mg administered every 2 weeks starting 1 week after the first dose. For a body weight ≥30 kg, the initial dose is 40 mg, with 40mg administered every 2 weeks starting 1 week after the first dose.

    Drug: Adalimumab Solution for Injection

Interventions

  • Adalimumab is a fully human anti-tumour necrosis factor-alpha monoclonal antibody that inhibits the downstream inflammatory cascade by blocking Tumor Necrosis Factor-α (TNF-α), a core inflammatory factor in psoriasis. In March 2020, adalimumab was approved in China for the treatment of severe plaque psoriasis in children and adolescents aged four years and older who have not responded well to topical therapies and phototherapy or are unsuitable for such treatments.

06

What researchers measure

Primary outcomes

  1. Psoriasis Area and Severity Index 75 at week 16

    The proportion of subjects achieving PASI 75 at week 16 (PASI score decreased by ≥75% from baseline).

    Time frame: Week 16

Secondary outcomes

  1. Psoriasis Area and Severity Index 75 at weeks 8, 32, and 52

    Proportion of subjects achieving PASI 75 at weeks 8, 32, and 52

    Time frame: Week 8, Week 32, Week 52

  2. Psoriasis Area and Severity Index 90

    Proportion of subjects achieving PASI 90 (PASI score decreased by ≥90% from baseline) at weeks 8, 16, 32, and 52

    Time frame: Week 8, Week 16, Week 32, Week 52

  3. Psoriasis Area and Severity Index 100

    Proportion of subjects achieving PASI 100 (100% reduction in PASI score from baseline) at Weeks 8, 16, 32 and 52

    Time frame: Week 8, Week 16, Week 32, Week 52

  4. Achieve a Physician's Global Assessment (PGA) score of clear (0) or very mild (1)

    Proportion of subjects who achieved a PGA score of clear (0) or almost clear (1) at weeks 8, 16, 32, and 52

    Time frame: Week 8, Week 16, Week 32, Week 52

  5. Children's Dermatology Life Quality Index (CDLQI) score

    The changes from baseline in the Children's Dermatology Life Quality Index (CDLQI) score at Weeks 8, 16, 32 and 52 were used to assess efficacy.

    Time frame: Week 8, Week 16, Week 32, Week 52

  6. Incidence of adverse events (AE), serious adverse events (SAE), adverse drug reactions (ADR), and serious ADRs

    Incidence of adverse events (AE), serious adverse events (SAE), adverse drug reactions (ADR), and serious ADRs

    Time frame: Up to 54 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Apr 2028, 23 months later.

Of 40 industry-sponsored phase 4 interventional studies under Psoriasis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's planned 23 months is close to that.

Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2026
First posted
Apr 14, 2026
StartEst.
May 2026
Primary completionEst.
Apr 2028
CompletionEst.
May 2028
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07529925
Responsible party
Sponsor
First posted
Apr 14, 2026
Start date
May 2026 (estimated)
Primary completion
Apr 2028 (estimated)
Completion
May 2028 (estimated)
Last update
Apr 14, 2026

Study contacts

Bin Yang, Doctor
Contact
yangbin101@hotmail.com
13922207231

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion